시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 펩타이드 및 항응고제 시장 보고서(2025년)
Peptide And Anticoagulant Drugs Global Market Report 2025
상품코드 : 1815892
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,527,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,434,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,341,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

펩타이드 및 항응고제 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 9.9%를 나타내 22억 5,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 만성질환의 유병률 상승, 고령화, 암 유병률 상승, 신흥 시장 확대, 심혈관질환 부담 증가에 기인하고 있습니다. 예측 기간의 주요 동향으로는 생명공학의 진보, 약물전달의 기술 개발, 진단기술의 향상, 약리학의 진보, 항응고제품의 개발 등을 들 수 있습니다.

향후 5년간의 성장률 9.9%라는 예측은 이 시장의 전회 예측으로부터 0.4%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 독일과 일본에서 수입되는 펩타이드계 항응고제의 비용을 상승시키고, 뇌졸중 예방의 선택을 줄이고, 심혈관 치료비를 상승시킬 수 있기 때문에 순환기 내과 진료에 큰 과제를 초래할 수 있습니다. 또한 상호 관세와 무역 긴장 증가와 제한으로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더 광범위하게 늘어날 것입니다.

만성 질환의 유병률 증가는 펩타이드 및 항응고제 시장 성장을 가속할 것으로 예측됩니다. 만성 질환은 수년 동안 또는 평생 지속되는 장기 건강 상태입니다. 인구의 고령화, 건강에 해로운 라이프스타일, 비만, 고혈압, 당뇨병 등의 위험 인자 증가 등의 요인이 만성 질환의 부담 증가에 기여하고 있습니다. 펩타이드 및 항응고제는 심혈관질환, 혈전증, 뇌졸중 등의 질환을 관리하는데 있어서 혈전을 예방하고 환자의 결과를 개선하기 위해 특정 질환 경로를 표적으로 함으로써 중요한 역할을 하고 있습니다. 예를 들어 2023년 5월 미국 질병예방관리센터(CDC)의 보고에 따르면 2022년 심장병 및 암으로 인한 사망자 수는 69만 5,547명에 달했으며 2021년 60만 5,213명에서 증가했습니다. 그 결과 만성질환의 유병률 상승이 펩타이드 및 항응고제 시장 확대에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Peptide and anticoagulant drugs are therapeutic agents where peptide drugs are short chains of amino acids that mimic natural biological molecules, and anticoagulant drugs prevent blood clotting by inhibiting clotting factors. Some anticoagulants, such as hirudin and bivalirudin, are peptide-based, directly inhibiting thrombin to prevent thrombosis. These drugs are crucial in treating conditions such as deep vein thrombosis, pulmonary embolism, and stroke.

The main types of peptide and anticoagulant drugs are hormonal, antibiotic, ACE inhibitor, antifungal, and other types. Hormonal drugs, including peptide-based hormones such as insulin and GLP-1 analogs, regulate hormone levels to treat conditions such as diabetes, while peptide and anticoagulant drugs provide targeted therapies for managing chronic diseases. These drugs can be administered through various routes, including oral, injectable, and other methods, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and others. Their applications span a wide range of medical fields, including infectious diseases, gynecology, cancer, diabetes, cardiology, osteoporosis, and others. End-users of these drugs include hospitals, specialty clinics, home care settings, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The peptide and anticoagulant drugs market research report is one of a series of new reports from The Business Research Company that provides peptide and anticoagulant drugs market statistics, including the peptide and anticoagulant drugs industry global market size, regional shares, competitors with the peptide and anticoagulant drugs market share, detailed peptide and anticoagulant drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the peptide and anticoagulant drugs industry. This peptide and anticoagulant drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The peptide and anticoagulant drugs market size has grown strongly in recent years. It will grow from $1.41 billion in 2024 to $1.54 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to increased healthcare expenditure, increased healthcare investments, rising market liberalization, a rise in the number of infected patients globally, and an increase in the incidence of genetic conditions.

The peptide and anticoagulant drugs market size is expected to see strong growth in the next few years. It will grow to $2.25 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to the rising prevalence of chronic diseases, aging population, rising prevalence of cancer, emerging markets expansion, and increasing burden of cardiovascular diseases. Major trends in the forecast period include advancements in biotechnology, technological developments in drug delivery, improved diagnostic techniques, advancements in pharmacology, and the development of anticoagulant products.

The forecast of 9.9% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for cardiology practices by increasing costs of peptide-based anticoagulants imported from Germany and Japan, potentially reducing stroke prevention options and raising cardiovascular care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of chronic diseases is expected to drive the growth of the peptide and anticoagulant drugs market. Chronic diseases are long-term health conditions that persist for years or even a lifetime. Factors such as aging populations, unhealthy lifestyles, and a rise in risk factors such as obesity, hypertension, and diabetes contribute to the growing burden of chronic diseases. Peptide and anticoagulant drugs play a crucial role in managing conditions such as cardiovascular diseases, thrombosis, and stroke by preventing blood clots and targeting specific disease pathways for better patient outcomes. For example, in May 2023, reports from the Centers for Disease Control and Prevention (CDC) indicated that heart disease and cancer deaths reached 695,547 in 2022, an increase from 605,213 in 2021. As a result, the rising prevalence of chronic diseases is fueling the expansion of the peptide and anticoagulant drugs market.

Companies in the peptide and anticoagulant drugs market are focusing on advancements in anticoagulant therapies, such as oral anticoagulants, to enhance efficacy, improve patient compliance, and reduce the risk of bleeding complications. Oral anticoagulants are medications taken by mouth to prevent blood clots by inhibiting clotting factors in the blood. For instance, in April 2024, Cadrenal Therapeutics Inc., a US-based pharmaceutical company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for tecarfarin, its late-stage oral anticoagulant. Tecarfarin is a novel, reversible blood thinner designed to reduce the risk of heart attacks, strokes, and mortality associated with blood clots in patients with rare cardiovascular conditions. The ODD applies specifically to preventing thromboembolism and thrombosis in patients with implanted mechanical circulatory support devices, including left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), ventricular assist devices (VADs), biventricular assist devices, and total artificial hearts.

In September 2023, Biosynth, a Switzerland-based provider of complex chemicals and biological materials, acquired Pepceuticals for an undisclosed amount. This acquisition aims to strengthen Biosynth's capabilities in developing and manufacturing peptide-based therapeutics and biomaterials. The strategic move expands Biosynth's presence in the life sciences sector, offering a broader portfolio of advanced solutions for the pharmaceutical and biotechnology industries. Pepceuticals Ltd is a UK-based manufacturer specializing in synthetic peptides.

Major players in the peptide and anticoagulant drugs market are Pfizer Inc., Merck & Co. Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Sanofi S.A., Abbott Laboratories, Novartis AG, Novo Nordisk A/S, Viatris Inc., Baxter International Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Bachem Holding AG, Bharat Serums and Vaccines Limited, Wockhardt Limited, AmbioPharm Inc., MITS Healthcare Private Limited, Siddha Pharmacy, Circle Pharma Inc., and Tenwel Pharmaceuticals Pvt. Ltd.

North America was the largest region in the peptide and anticoagulant drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in peptide and anticoagulant drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the peptide and anticoagulant drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptide and anticoagulant drugs market consists of sales of peptide-based drugs and heparins. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide And Anticoagulant Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peptide and anticoagulant drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for peptide and anticoagulant drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peptide and anticoagulant drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Peptide And Anticoagulant Drugs Market Characteristics

3. Peptide And Anticoagulant Drugs Market Trends And Strategies

4. Peptide And Anticoagulant Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Peptide And Anticoagulant Drugs Growth Analysis And Strategic Analysis Framework

6. Peptide And Anticoagulant Drugs Market Segmentation

7. Peptide And Anticoagulant Drugs Market Regional And Country Analysis

8. Asia-Pacific Peptide And Anticoagulant Drugs Market

9. China Peptide And Anticoagulant Drugs Market

10. India Peptide And Anticoagulant Drugs Market

11. Japan Peptide And Anticoagulant Drugs Market

12. Australia Peptide And Anticoagulant Drugs Market

13. Indonesia Peptide And Anticoagulant Drugs Market

14. South Korea Peptide And Anticoagulant Drugs Market

15. Western Europe Peptide And Anticoagulant Drugs Market

16. UK Peptide And Anticoagulant Drugs Market

17. Germany Peptide And Anticoagulant Drugs Market

18. France Peptide And Anticoagulant Drugs Market

19. Italy Peptide And Anticoagulant Drugs Market

20. Spain Peptide And Anticoagulant Drugs Market

21. Eastern Europe Peptide And Anticoagulant Drugs Market

22. Russia Peptide And Anticoagulant Drugs Market

23. North America Peptide And Anticoagulant Drugs Market

24. USA Peptide And Anticoagulant Drugs Market

25. Canada Peptide And Anticoagulant Drugs Market

26. South America Peptide And Anticoagulant Drugs Market

27. Brazil Peptide And Anticoagulant Drugs Market

28. Middle East Peptide And Anticoagulant Drugs Market

29. Africa Peptide And Anticoagulant Drugs Market

30. Peptide And Anticoagulant Drugs Market Competitive Landscape And Company Profiles

31. Peptide And Anticoagulant Drugs Market Other Major And Innovative Companies

32. Global Peptide And Anticoagulant Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Peptide And Anticoagulant Drugs Market

34. Recent Developments In The Peptide And Anticoagulant Drugs Market

35. Peptide And Anticoagulant Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기